Amphastar Pharmaceuticals, Inc. (AMPH) — Analysis Summary
Amphastar Pharmaceuticals, Inc. (AMPH) has a market cap of $1.02B with year-over-year revenue growth of -1.7%. Net margin stands at 13.6%. The stock trades at a P/E ratio of 12.9.
Key Takeaways
- Revenue changed -1.7% year-over-year
- Net margin of 13.6%
- P/E ratio of 12.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, AMPH posted revenue growth of -1.7% and trades at a P/E of 12.9.
Amphastar Pharmaceuticals, Inc. (AMPH)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Debt/EBITDA at 4.2x — elevated leverage
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1,976
Headquarters
RANCHO CUCAMONGA, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.